|

Arthritis Clinical Trials in Charlotte, NC

29 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD—<1 mi
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.Phase 2<1 mi
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry—<1 mi
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic ArthritisPhase 3<1 mi
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic ArthritisPhase 3<1 mi
Nipocalimab in Moderate to Severe Sjogren's DiseasePhase 3<1 mi
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesPhase 3<1 mi
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.Phase 3<1 mi
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisPhase 2<1 mi
A Long-term Extension Study of Ustekinumab in Pediatric ParticipantsPhase 3<1 mi
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)—<1 mi
Clinical Outcomes Study of the Nexel Total ElbowN/A<1 mi
A Study of Dotinurad Versus Allopurinol in Participants With GoutPhase 3<1 mi
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic ArthritisPhase 2<1 mi
Z1 Hip System: Post-Market Clinical Follow Up Study—<1 mi
Primary Subtalar Arthrodesis for Calcaneal FracturesN/A<1 mi
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).Phase 1<1 mi
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponsePhase 3<1 mi
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed PatientsPhase 2<1 mi
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic ArthritisPhase 3<1 mi
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightPhase 310 mi
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))N/A20 mi
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugPhase 337 mi
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromePhase 337 mi
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid ArthritisPhase 237 mi
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)Phase 437 mi
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)Phase 337 mi
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneePhase 339 mi
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesPhase 345 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.